Cargando…

Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis

BACKGROUND: The elevated calcium and phosphorus levels in patients undergoing hemodialysis may increase the risk of all-cause mortality. Paricalcitol, as a new vitamin D receptor activator (VDRA), seemed to be effective in reducing the calcium and phosphorus levels. OBJECTIVES: The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yang, Liu, Ling-Yun, Jia, Ye, Wu, Mei-Yan, Sun, Yan-Yan, Ma, Fu-Zhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445244/ https://www.ncbi.nlm.nih.gov/pubmed/30992658 http://dx.doi.org/10.2147/DDDT.S176257

Ejemplares similares

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
por: Izquierdo, María Jesús, et al.
Publicado: (2012)

Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
por: Han, Tianzhao, et al.
Publicado: (2013)

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2021)

A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials
por: Geng, Xinghua, et al.
Publicado: (2020)

Efficacy of atorvastatin on the prevention of contrast-induced acute kidney injury: a meta-analysis
por: Liu, Ling-Yun, et al.
Publicado: (2018)

Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol
por: Oliva-Damaso, Elena, et al.
Publicado: (2016)

Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease
por: Webb, Nicholas J. A., et al.
Publicado: (2017)

Effectiveness and Safety of Ultrasound-Guided Local Paricalcitol Injection in Treating Secondary Hyperparathyroidism in ESRD: A Retrospective Study
por: Xie, Shuqin, et al.
Publicado: (2022)

Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients
por: Zheng, Jing-Quan, et al.
Publicado: (2016)

Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials
por: Xie, Yifeng, et al.
Publicado: (2017)

Effects of paricalcitol combined with hemodiafiltration on bone-metabolism-related indexes in patients with diabetic nephropathy and chronic renal failure
por: Ma, Xiao-Ying, et al.
Publicado: (2023)

Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol
por: Mimura, Luiza Ayumi Nishiyama, et al.
Publicado: (2021)

Antiapoptotic Effect of Paricalcitol in Gentamicin-induced Kidney Injury
por: Suh, Sang Heon, et al.
Publicado: (2013)

Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis
por: Gu, Hai-Feng, et al.
Publicado: (2015)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

High prevalence of sarcopenia and myosteatosis in patients undergoing hemodialysis
por: Fu, Chen, et al.
Publicado: (2023)

Role of microRNA-15a-5p in the atherosclerotic inflammatory response and arterial injury improvement of diabetic by targeting FASN
por: Liu, Yang, et al.
Publicado: (2019)

Comparison of the Pharmacological Effects of Paricalcitol and Doxercalciferol on the Factors Involved in Mineral Homeostasis
por: Wu-Wong, J. Ruth, et al.
Publicado: (2010)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis
por: Stavenuiter, Andrea W. D., et al.
Publicado: (2015)

Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease
por: Lucisano, Silvia, et al.
Publicado: (2015)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Effects of Paricalcitol on Body Composition in Vitamin D-Deficient Rats
por: Koohpeyma, Farhad, et al.
Publicado: (2021)

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation
por: D’Marco, Luis, et al.
Publicado: (2022)

Efficacy and safety of expanded hemodialysis in hemodialysis patients: a meta-analysis and systematic review
por: Zhao, Yuchao, et al.
Publicado: (2022)

Efficacy and Safety of Neuromuscular Blockade in Overweight Patients Undergoing Nasopharyngeal Surgery
por: Niu, Lingxia, et al.
Publicado: (2020)

Therapeutic Efficacy and Safety of Paeoniae Radix Rubra Formulae in Relieving Hyperbilirubinemia Induced by Viral Hepatitis: A Meta-Analysis
por: Huang, Yin-Qiu, et al.
Publicado: (2016)

Nursing Strategies for Patients with Chronic Renal Failure Undergoing Maintenance Hemodialysis Treatment by Arteriovenous Fistula
por: QIN, Hong Yan, et al.
Publicado: (2016)

Cardiac and Renal Effects of Atrasentan in Combination with Enalapril and Paricalcitol in Uremic Rats
por: Ritter, Cynthia, et al.
Publicado: (2014)

The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
por: Zhao, Cong, et al.
Publicado: (2022)

The Efficacy and Safety of Topiramate in the Prevention of Pediatric Migraine: An Update Meta-Analysis
por: Wu, Xinwei, et al.
Publicado: (2020)

Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients
por: Zeng, Qian, et al.
Publicado: (2023)

Paricalcitol Ameliorates Acute Kidney Injury in Mice by Suppressing Oxidative Stress and Inflammation via Nrf2/HO-1 Signaling
por: Wang, Shuang, et al.
Publicado: (2023)

Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis
por: Shigematsu, Takashi, et al.
Publicado: (2020)

Efficacy and safety of Tongdutiaoshen acupuncture on insomnia in maintenance hemodialysis patients: A randomized clinical trial protocol
por: Wang, Pei, et al.
Publicado: (2023)

Efficacy and Safety of Tranexamic Acid in Pediatric Patients Undergoing Cardiac Surgery: A Single-Center Experience
por: Zhang, Yu, et al.
Publicado: (2019)

Safety and efficacy of the Tablo hemodialysis system for in‐center and home hemodialysis
por: Plumb, Troy J., et al.
Publicado: (2019)

Paricalcitol Improves Hypoxia-Induced and TGF-β1-Induced Injury in Kidney Pericytes
por: Lim, Jeong-Hoon, et al.
Publicado: (2021)

The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control
por: Cozzolino, Mario, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_21fei706j7t4av16anev8m22t6